We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




AI-Based Pathology Diagnosis Tool Detects Seven Types of Gastric Cancer

By LabMedica International staff writers
Posted on 09 Sep 2022

There is increasing demand for diagnostic tools that can help reduce the workload of pathologists. More...

Now, researchers developing an AI-based pathology diagnostic tool have succeeded in expanding its AI detection to seven types of gastric cancer, highlighting its versatility for a range of pathology applications.

Evident (Waltham, MA, USA), a wholly owned subsidiary of Olympus Corporation, announced the latest results from its ongoing joint research program to create an AI-based pathology diagnostic tool at the 20th annual meeting of the Japanese Society of Digital Pathology. In 2017, Evident along with collaborators had begun to develop the AI-based pathology diagnosis tool. The first testing phase showed the diagnostic tool could successfully identify adenocarcinoma tissue from pathology whole-slide images. As part of the second research phase that began in November 2020, the tool was tested on 2,717 pathology whole-slide images provided by six hospitals in Japan to improve its versatility and accuracy.

By significantly increasing the amount of image data through collaboration with the hospitals, the diagnostic tool improved its AI detection of adenocarcinoma of tubular and poorly differentiated types and expanded its AI detection to identify other gastric cancers. It achieved a false negative rate of 0 to 2.5% in seven types of gastric cancer: adenocarcinoma, of tubular, papillary, mucinous and poorly differentiated types, gastrointestinal stromal tumor, MALT lymphoma, and diffuse large B-cell lymphoma. A common AI discrimination threshold was set for all hospitals, demonstrating the improved versatility of the software. As the second research phase continues, Evident aims to further refine the tool to prepare it for commercial use. The goal of this program is to deliver an AI pathology diagnosis software that can assist pathologists by 2023.

Related Links:
Evident


New
Gold Member
Latex Test
SLE-Latex Test
Serological Pipet Controller
PIPETBOY GENIUS
New
PlGF Test
Quidel Triage PlGF Test
New
Automated PCR Setup
ESTREAM
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Molecular Diagnostics

view channel
Image: The RNA-seq based diagnostic test for pediatric leukemia ensures better outcomes for children with this common cancer (Photo courtesy of Qlucore)

RNA-Seq Based Diagnostic Test Enhances Diagnostic Accuracy of Pediatric Leukemia

A new unique test is set to reshape the way Acute Lymphoblastic Leukemia (BCP-ALL) samples can be analyzed. Qlucore (Lund, Sweden) has launched the first CE-marked RNA-seq based diagnostic test for pediatric... Read more

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.